Published in Prostate on November 01, 2009
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst (2014) 1.90
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther (2011) 1.24
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 1.21
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron (2012) 1.05
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy (2014) 1.02
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med (2011) 1.01
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res (2011) 0.99
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 0.97
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget (2015) 0.94
Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med (2011) 0.94
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer (2014) 0.92
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology (2012) 0.88
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol (2013) 0.87
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate (2011) 0.86
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol (2012) 0.85
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res (2014) 0.84
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int J Clin Exp Pathol (2015) 0.83
Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia. J Virol (2012) 0.82
Update: immunological strategies for prostate cancer. Curr Urol Rep (2010) 0.82
Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer (2013) 0.82
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov (2016) 0.82
Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget (2016) 0.81
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol (2014) 0.80
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol (2014) 0.79
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol (2011) 0.78
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res (2014) 0.77
PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study. Medicine (Baltimore) (2016) 0.77
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev (2016) 0.76
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol (2017) 0.76
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther (2016) 0.75
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget (2017) 0.75
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer (2016) 0.75
Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget (2017) 0.75
PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett (2017) 0.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
A direct estimate of the human alphabeta T cell receptor diversity. Science (1999) 6.85
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol (2006) 5.46
Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol (2002) 4.25
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2005) 3.46
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Human T-cell receptor variable gene segment families. Immunogenetics (1995) 2.86
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother (2004) 1.54
Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res (2005) 1.45
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate (1998) 1.07
Selective accumulation of related CD4+ T cell clones in the synovial fluid of patients with rheumatoid arthritis. J Immunol (1998) 1.04
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01
Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate (2007) 0.95
T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res (1997) 0.91
Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin Immunol (2006) 0.86
Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. J Immunol (2009) 0.85
Analysis of T cell repertoire in the liver of patients with chronic hepatitis C. Clin Exp Immunol (2000) 0.85
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate (2011) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate (2005) 2.18
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 2.07
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95